Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
- PMID: 30676837
- PMCID: PMC6479238
- DOI: 10.1089/jop.2018.0090
Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States
Abstract
Introduction: Repository corticotropin injection (RCI) has immune-modulatory and anti-inflammatory effects and is approved for multiple indications, including severe and acute chronic allergic and inflammatory processes involving the eye and adnexa. This study describes patient characteristics, treatment patterns, and physicians' assessments of patients with uveitis treated with RCI.
Methods: This was a retrospective medical record review of US patients. Eligible patients had a diagnosis of uveitis, received RCI in the past 12 months, and had completed or were receiving RCI treatment at the time of data collection. Baseline characteristics and after-treatment clinical data are descriptively reported.
Results: The study included 91 patients (mean age 41 years, 62% female, and mean time since diagnosis 3.98 years). Most patients had moderate (n = 48, 53%) to severe (n = 21, 23%) visual impairment, and none was blind before RCI therapy. Patients used an average of 2.5 medications before RCI. Initial RCI dosing regimens, dose adjustments, and treatment durations were different for each patient. Concomitant medication use and dosages were reduced during RCI; 76 patients (84%) improved, 15 patients (16%) stayed the same, and none worsened; 86% of patients had improvements in vision.
Conclusions: Physicians individualized RCI therapy among patients who suffered uveitis for several years and when previous therapies were inadequate. Most patients improved after initiating RCI, most commonly in vision. The findings support use of RCI for uveitis and provide a better understanding of patient characteristics and practice patterns to guide appropriate use.
Keywords: ACTH; RCI; drug therapy; health care utilization; repository corticotropin injection; uveitis.
Conflict of interest statement
All authors had full access to all of the data in this study. All named authors meet the International Committee of Medical Journal Editors (ICJME) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given approval for this version to be published. W.W.N., A.F.L., J.K., B.O.-O., and G.C. are employees of Mallinckrodt Pharmaceuticals and declare that they have no other conflicts of interest. J.R.G., K.H., and S.C. were research consultants for the study and declare that they have no conflicts of interest.
Figures
Similar articles
-
Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.Adv Ther. 2022 Jul;39(7):3072-3087. doi: 10.1007/s12325-022-02176-4. Epub 2022 May 30. Adv Ther. 2022. PMID: 35635646 Free PMC article. Review.
-
Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619888127. doi: 10.1177/1753466619888127. Ther Adv Respir Dis. 2019. PMID: 31722624 Free PMC article.
-
Management of repository corticotropin injection therapy for non-infectious uveitis: a Delphi study.Acta Ophthalmol. 2021 Sep;99(6):669-678. doi: 10.1111/aos.14702. Epub 2021 Mar 9. Acta Ophthalmol. 2021. PMID: 33751822 Free PMC article.
-
Outcomes of Repository Corticotropin Gel for Ocular Sarcoidosis.Ocul Immunol Inflamm. 2022 Aug;30(6):1420-1424. doi: 10.1080/09273948.2021.1884887. Epub 2021 Apr 7. Ocul Immunol Inflamm. 2022. PMID: 33826473
-
Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.Adv Ther. 2017 Aug;34(8):1775-1790. doi: 10.1007/s12325-017-0569-9. Epub 2017 Jun 28. Adv Ther. 2017. PMID: 28660550 Free PMC article. Review.
Cited by
-
Treatment with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Dermatomyositis/Polymyositis.Open Access Rheumatol. 2020 Feb 20;12:21-28. doi: 10.2147/OARRR.S231667. eCollection 2020. Open Access Rheumatol. 2020. PMID: 32110122 Free PMC article.
-
The Therapeutic Effects of Purified Cortrophin Gel on Experimental Autoimmune Uveitis.Ocul Immunol Inflamm. 2025 Jul 22:1-9. doi: 10.1080/09273948.2025.2532821. Online ahead of print. Ocul Immunol Inflamm. 2025. PMID: 40694652 Free PMC article.
-
Pain and Fatigue Improvements in Patients Treated with Repository Corticotropin Injection Across Five Indications: A Narrative Review.Adv Ther. 2022 Jul;39(7):3072-3087. doi: 10.1007/s12325-022-02176-4. Epub 2022 May 30. Adv Ther. 2022. PMID: 35635646 Free PMC article. Review.
-
The Role of Retinal Pigment Epithelial Cells in Regulation of Macrophages/Microglial Cells in Retinal Immunobiology.Front Immunol. 2021 Aug 13;12:724601. doi: 10.3389/fimmu.2021.724601. eCollection 2021. Front Immunol. 2021. PMID: 34484232 Free PMC article. Review.
-
Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina.Int J Mol Sci. 2023 Apr 8;24(8):6928. doi: 10.3390/ijms24086928. Int J Mol Sci. 2023. PMID: 37108092 Free PMC article.
References
-
- Mustafa M., Muthusamy P., Hussain S.S., Shimmi S.C., and Sein M.M. Uveitis: pathogenesis, clinical presentations and treatment. IOSR J. Pharm. 4:42–47, 2014
-
- Guly C.M., and Forrester J.V. Investigation and management of uveitis. BMJ 341:c4976, 2010 - PubMed
-
- Acharya N.R., Tham V.M., Esterberg E., Borkar D.S., Parker J.V., Vinoya A.C., and Uchida A. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 131:1405–1412, 2013 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous